Sonorous Neurovascular received FDA breakthrough device designation for its BosSTENT device intended to treat pulsatile tinnitus, the company announced.
“The BosSTENT represents years of focused innovation to deliver an on-label, minimally invasive solution that normalizes...
Sonorous Neurovascular received FDA breakthrough device designation for its BosSTENT device intended to treat pulsatile tinnitus, the company announced.
“The BosSTENT represents years of focused...
Median Technologies, developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a...
The massive $330 million fund from Santé Ventures signals a major shift toward high-complexity MedTech and digital health. With industry deal value reaching a...
Artivion has debuted long-term clinical data on two of its cardiac stent products, revealing each’s solution’s potential to offer extended benefits to patients.
This includes...
Biotronik announced the successful first-in-human implantations of its LivIQ leadless pacemaker system.
The implants came in Australia as part of the company’s BIO|CONCEPT.LivIQ study, a...
Robocath announced that it launched a first-in-human clinical study evaluating its new robotic system in coronary artery disease.
The Rouen, France-based company said its second-generation...
ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced the...
Sonorous Neurovascular received FDA breakthrough device designation for its BosSTENT device intended to treat pulsatile tinnitus, the company announced.
“The BosSTENT represents years of focused...
Median Technologies, developer of eyonis, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a...
The massive $330 million fund from Santé Ventures signals a major shift toward high-complexity MedTech and digital health. With industry deal value reaching a...